Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 102.48M USD.
Valorada de forma justa
El PE más reciente de la empresa es -1.48, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 7.58M acciones, lo que supone un aumento del 2.79% con respecto al trimestre anterior.
En posesión de Steven Cohen
El inversor estrella Steven Cohen posee 580.67K acciones de este valor.